<DOC>
	<DOCNO>NCT02373462</DOCNO>
	<brief_summary>To study effect olmesartan walk distance quality life peripheral artery disease patient hypertension treat For intermittent claudication .</brief_summary>
	<brief_title>Effect olmesaRtan Walking distancE quaLIty lifE Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication ( RELIEF )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Aged 20 85 year visit 1 Patients anklebrachial index ( ABI ) less 0.9 one legs history intermittent claudication stable previous 6 month Patients whose statin , anti hypertensive medication antiplatelet medication stable past 6 month . Statins cilostazol allow need stable past 6 month ( diabetic medication may change ) Patients whose blood pressure 140/90 mmHg with/without antihypertension treatment Blood pressure 180/110 mmHg Patients take ARBs ACE inhibitor treatment least 6 month Patients take aldosterone receptor antagonist least 6 month Patients serum creatinine 3 mg/dL serum potassium ( K+ ) &gt; 5.5mg/dl History bilateral renal artery stenosis History acute coronary syndrome heart failure hospitalization within 6 month Peripheral arterial revascularization plan within 1 month Critical limb ischemia Patients impaired cognition ( e.g . dementia ) pregnancy woman age childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>